Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats

Tatsuo Yamamoto, Osamu Saito, Tomohiko Aoe, Alessandra Bartolozzi, Jayaprakash Sarva, Jia Zhou, Alan Kozikowski, Barbara Wroblewska, Tomasz Bzdega, Joseph H. Neale

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The peptide neurotransmitter N-acetylaspartylglutamate (NAAG) selectively activates group II metabotropic glutamate receptors (mGluRs). Systemic administration of inhibitors of the enzymes that inactivate NAAG results in decreased pain responses in rat models of inflammatory and neuropathic pain. These effects are blocked by a group II mGluR antagonist. This research tested the hypothesis that some analgesic effects of NAAG peptidase inhibition are mediated by NAAG acting on sensory neurite mGluRs at the site of inflammation. Group II mGluR agonists, SLx-3095-1, NAAG and APDC, or NAAG peptidase inhibitors, ZJ-43 and 2-PMPA, injected into the rat footpad reduced pain responses in carrageenan or formalin models. The analgesic effects of SLx-3095-1, APDC, ZJ-43, 2-PMPA and NAAG were blocked by co-injection of LY341495, a selective group II mGluR antagonist. Injection of group II mGluR agonists, NAAG or the peptidase inhibitors into the contralateral rat footpad had no effect on pain perception in the injected paw. At 10-100 μm ZJ-43 and 2-PMPA demonstrated no consistent agonist activity at mGluR2 or mGluR3. Consistent with the conclusion that peripherally administered NAAG peptidase inhibitors increase the activation of mGluR3 by NAAG that is released from peripheral sensory neurites, we found that the tissue average concentration of NAAG in the unstimulated rat hind paw was about 6 μm. These data extend our understanding of the role of this peptide in sensory neurons and reveal the potential for treatment of inflammatory pain via local application of NAAG peptidase inhibitors at doses that may have little or no central nervous system effects.

Original languageEnglish (US)
Pages (from-to)147-158
Number of pages12
JournalEuropean Journal of Neuroscience
Volume25
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Glutamate Carboxypeptidase II
Protease Inhibitors
Analgesics
Pain
Metabotropic Glutamate Receptors
Neurites
LY 341495
Peptides
Pain Perception
Injections
Carrageenan
Neuralgia
Enzyme Inhibitors
Sensory Receptor Cells
N-acetyl-1-aspartylglutamic acid
Formaldehyde
Neurotransmitter Agents
Central Nervous System
Inflammation

Keywords

  • Carrageenan
  • Group II mGluRs
  • Inflammatory pain
  • LY 341495
  • NAAG
  • Sensory neurons

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. / Yamamoto, Tatsuo; Saito, Osamu; Aoe, Tomohiko; Bartolozzi, Alessandra; Sarva, Jayaprakash; Zhou, Jia; Kozikowski, Alan; Wroblewska, Barbara; Bzdega, Tomasz; Neale, Joseph H.

In: European Journal of Neuroscience, Vol. 25, No. 1, 01.2007, p. 147-158.

Research output: Contribution to journalArticle

Yamamoto, T, Saito, O, Aoe, T, Bartolozzi, A, Sarva, J, Zhou, J, Kozikowski, A, Wroblewska, B, Bzdega, T & Neale, JH 2007, 'Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats', European Journal of Neuroscience, vol. 25, no. 1, pp. 147-158. https://doi.org/10.1111/j.1460-9568.2006.05272.x
Yamamoto, Tatsuo ; Saito, Osamu ; Aoe, Tomohiko ; Bartolozzi, Alessandra ; Sarva, Jayaprakash ; Zhou, Jia ; Kozikowski, Alan ; Wroblewska, Barbara ; Bzdega, Tomasz ; Neale, Joseph H. / Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. In: European Journal of Neuroscience. 2007 ; Vol. 25, No. 1. pp. 147-158.
@article{f287d99c712d4d3492cfabed1db1d73b,
title = "Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats",
abstract = "The peptide neurotransmitter N-acetylaspartylglutamate (NAAG) selectively activates group II metabotropic glutamate receptors (mGluRs). Systemic administration of inhibitors of the enzymes that inactivate NAAG results in decreased pain responses in rat models of inflammatory and neuropathic pain. These effects are blocked by a group II mGluR antagonist. This research tested the hypothesis that some analgesic effects of NAAG peptidase inhibition are mediated by NAAG acting on sensory neurite mGluRs at the site of inflammation. Group II mGluR agonists, SLx-3095-1, NAAG and APDC, or NAAG peptidase inhibitors, ZJ-43 and 2-PMPA, injected into the rat footpad reduced pain responses in carrageenan or formalin models. The analgesic effects of SLx-3095-1, APDC, ZJ-43, 2-PMPA and NAAG were blocked by co-injection of LY341495, a selective group II mGluR antagonist. Injection of group II mGluR agonists, NAAG or the peptidase inhibitors into the contralateral rat footpad had no effect on pain perception in the injected paw. At 10-100 μm ZJ-43 and 2-PMPA demonstrated no consistent agonist activity at mGluR2 or mGluR3. Consistent with the conclusion that peripherally administered NAAG peptidase inhibitors increase the activation of mGluR3 by NAAG that is released from peripheral sensory neurites, we found that the tissue average concentration of NAAG in the unstimulated rat hind paw was about 6 μm. These data extend our understanding of the role of this peptide in sensory neurons and reveal the potential for treatment of inflammatory pain via local application of NAAG peptidase inhibitors at doses that may have little or no central nervous system effects.",
keywords = "Carrageenan, Group II mGluRs, Inflammatory pain, LY 341495, NAAG, Sensory neurons",
author = "Tatsuo Yamamoto and Osamu Saito and Tomohiko Aoe and Alessandra Bartolozzi and Jayaprakash Sarva and Jia Zhou and Alan Kozikowski and Barbara Wroblewska and Tomasz Bzdega and Neale, {Joseph H.}",
year = "2007",
month = "1",
doi = "10.1111/j.1460-9568.2006.05272.x",
language = "English (US)",
volume = "25",
pages = "147--158",
journal = "European Journal of Neuroscience",
issn = "0953-816X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats

AU - Yamamoto, Tatsuo

AU - Saito, Osamu

AU - Aoe, Tomohiko

AU - Bartolozzi, Alessandra

AU - Sarva, Jayaprakash

AU - Zhou, Jia

AU - Kozikowski, Alan

AU - Wroblewska, Barbara

AU - Bzdega, Tomasz

AU - Neale, Joseph H.

PY - 2007/1

Y1 - 2007/1

N2 - The peptide neurotransmitter N-acetylaspartylglutamate (NAAG) selectively activates group II metabotropic glutamate receptors (mGluRs). Systemic administration of inhibitors of the enzymes that inactivate NAAG results in decreased pain responses in rat models of inflammatory and neuropathic pain. These effects are blocked by a group II mGluR antagonist. This research tested the hypothesis that some analgesic effects of NAAG peptidase inhibition are mediated by NAAG acting on sensory neurite mGluRs at the site of inflammation. Group II mGluR agonists, SLx-3095-1, NAAG and APDC, or NAAG peptidase inhibitors, ZJ-43 and 2-PMPA, injected into the rat footpad reduced pain responses in carrageenan or formalin models. The analgesic effects of SLx-3095-1, APDC, ZJ-43, 2-PMPA and NAAG were blocked by co-injection of LY341495, a selective group II mGluR antagonist. Injection of group II mGluR agonists, NAAG or the peptidase inhibitors into the contralateral rat footpad had no effect on pain perception in the injected paw. At 10-100 μm ZJ-43 and 2-PMPA demonstrated no consistent agonist activity at mGluR2 or mGluR3. Consistent with the conclusion that peripherally administered NAAG peptidase inhibitors increase the activation of mGluR3 by NAAG that is released from peripheral sensory neurites, we found that the tissue average concentration of NAAG in the unstimulated rat hind paw was about 6 μm. These data extend our understanding of the role of this peptide in sensory neurons and reveal the potential for treatment of inflammatory pain via local application of NAAG peptidase inhibitors at doses that may have little or no central nervous system effects.

AB - The peptide neurotransmitter N-acetylaspartylglutamate (NAAG) selectively activates group II metabotropic glutamate receptors (mGluRs). Systemic administration of inhibitors of the enzymes that inactivate NAAG results in decreased pain responses in rat models of inflammatory and neuropathic pain. These effects are blocked by a group II mGluR antagonist. This research tested the hypothesis that some analgesic effects of NAAG peptidase inhibition are mediated by NAAG acting on sensory neurite mGluRs at the site of inflammation. Group II mGluR agonists, SLx-3095-1, NAAG and APDC, or NAAG peptidase inhibitors, ZJ-43 and 2-PMPA, injected into the rat footpad reduced pain responses in carrageenan or formalin models. The analgesic effects of SLx-3095-1, APDC, ZJ-43, 2-PMPA and NAAG were blocked by co-injection of LY341495, a selective group II mGluR antagonist. Injection of group II mGluR agonists, NAAG or the peptidase inhibitors into the contralateral rat footpad had no effect on pain perception in the injected paw. At 10-100 μm ZJ-43 and 2-PMPA demonstrated no consistent agonist activity at mGluR2 or mGluR3. Consistent with the conclusion that peripherally administered NAAG peptidase inhibitors increase the activation of mGluR3 by NAAG that is released from peripheral sensory neurites, we found that the tissue average concentration of NAAG in the unstimulated rat hind paw was about 6 μm. These data extend our understanding of the role of this peptide in sensory neurons and reveal the potential for treatment of inflammatory pain via local application of NAAG peptidase inhibitors at doses that may have little or no central nervous system effects.

KW - Carrageenan

KW - Group II mGluRs

KW - Inflammatory pain

KW - LY 341495

KW - NAAG

KW - Sensory neurons

UR - http://www.scopus.com/inward/record.url?scp=33846260795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846260795&partnerID=8YFLogxK

U2 - 10.1111/j.1460-9568.2006.05272.x

DO - 10.1111/j.1460-9568.2006.05272.x

M3 - Article

VL - 25

SP - 147

EP - 158

JO - European Journal of Neuroscience

JF - European Journal of Neuroscience

SN - 0953-816X

IS - 1

ER -